BACKGROUND: Polymorphisms of the sex hormone-binding globulin (SHBG) gene are associated with differences in SHBG levels, influencing the risk for breast cancer and polycystic ovarian syndrome, but no association has been reported for osteoporosis in postmenopausal women. OBJECTIVE: To determine the effect of G to A substitution in the 5'UTR (rs1799941) and the Asp356Asn (rs6259) polymorphisms of the SHBG gene on bone mineral density (BMD). METHODS: This is a cross-sectional study in a university-based research center from May, 2002 to December, 2007. A total of two hundred and thirteen healthy postmenopausal Caucasian women > or = 1 year from last menstrual period participated to this study. Serum estradiol by ultrasensitive radioimmnunoassay, serum sex hormone-binding globulin by immunoradiometric assay, and urinary NTx by enzyme-linked immunoassay were measured. BMD measurements were performed by dual energy X-ray absorptiometry and genotyping by Pyrosequencing. RESULTS: There were no significant differences in SHBG levels associated with either rs1799941 or rs6259. Using a p value of <0.00625 for significance, we found that subjects with the A allele (GA+AA) for the rs1799941, had a trend for lower free estradiol index (FEI) compared to the GG genotype (p=0.04). They also had significantly lower BMD at the intertrochanter (p=0.003) and trend for lower BMD at the total hip (p=0.02). There was no significant difference in FEI levels between the genotypes for the rs6259 polymorphism, but women with the Asn allele (Asp/Asn+Asn/Asn), had significantly lower BMD in the total femur (p=0.004) and intertrochanter (0.002) compared to those with the Asp/Asp genotype. CONCLUSIONS: Our data suggest that polymorphisms of the SHBG gene are associated with significant differences in BMD at the proximal femur sites. Thus, genetic variations in the SHBG gene may influence BMD at the hip in postmenopausal women.
BACKGROUND: Polymorphisms of the sex hormone-binding globulin (SHBG) gene are associated with differences in SHBG levels, influencing the risk for breast cancer and polycystic ovarian syndrome, but no association has been reported for osteoporosis in postmenopausal women. OBJECTIVE: To determine the effect of G to A substitution in the 5'UTR (rs1799941) and the Asp356Asn (rs6259) polymorphisms of the SHBG gene on bone mineral density (BMD). METHODS: This is a cross-sectional study in a university-based research center from May, 2002 to December, 2007. A total of two hundred and thirteen healthy postmenopausal Caucasian women > or = 1 year from last menstrual period participated to this study. Serum estradiol by ultrasensitive radioimmnunoassay, serum sex hormone-binding globulin by immunoradiometric assay, and urinary NTx by enzyme-linked immunoassay were measured. BMD measurements were performed by dual energy X-ray absorptiometry and genotyping by Pyrosequencing. RESULTS: There were no significant differences in SHBG levels associated with either rs1799941 or rs6259. Using a p value of <0.00625 for significance, we found that subjects with the A allele (GA+AA) for the rs1799941, had a trend for lower free estradiol index (FEI) compared to the GG genotype (p=0.04). They also had significantly lower BMD at the intertrochanter (p=0.003) and trend for lower BMD at the total hip (p=0.02). There was no significant difference in FEI levels between the genotypes for the rs6259 polymorphism, but women with the Asn allele (Asp/Asn+Asn/Asn), had significantly lower BMD in the total femur (p=0.004) and intertrochanter (0.002) compared to those with the Asp/Asp genotype. CONCLUSIONS: Our data suggest that polymorphisms of the SHBG gene are associated with significant differences in BMD at the proximal femur sites. Thus, genetic variations in the SHBG gene may influence BMD at the hip in postmenopausal women.
Authors: Tarja Kalme; Markku Seppälä; Qing Qiao; Riitta Koistinen; Aulikki Nissinen; Maija Harrela; Mikko Loukovaara; Pekka Leinonen; Jaakko Tuomilehto Journal: J Clin Endocrinol Metab Date: 2004-12-21 Impact factor: 5.958
Authors: Annette Hammes; Thomas K Andreassen; Robert Spoelgen; Jens Raila; Norbert Hubner; Herbert Schulz; Jochen Metzger; Florian J Schweigert; Peter B Luppa; Anders Nykjaer; Thomas E Willnow Journal: Cell Date: 2005-09-09 Impact factor: 41.582
Authors: F Berrino; P Muti; A Micheli; G Bolelli; V Krogh; R Sciajno; P Pisani; S Panico; G Secreto Journal: J Natl Cancer Inst Date: 1996-03-06 Impact factor: 13.506
Authors: A Zeleniuch-Jacquotte; R E Shore; K L Koenig; A Akhmedkhanov; Y Afanasyeva; I Kato; M Y Kim; S Rinaldi; R Kaaks; P Toniolo Journal: Br J Cancer Date: 2004-01-12 Impact factor: 7.640
Authors: Lu Shun Zhang; Fang Yuan; Xuan Guan; Juan Li; Xin Lian Liu; Jing Sun; Bo Liu; Wei Ma; Feng Mei Deng Journal: Pathol Oncol Res Date: 2014-02-22 Impact factor: 3.201
Authors: Eva Lundin; Isaac Wirgin; Annekatrin Lukanova; Yelena Afanasyeva; Vittorio Krogh; Tomas Axelsson; Kari Hemminki; Tess V Clendenen; Alan A Arslan; Nina Ohlson; Sabina Sieri; Nirmal Roy; Karen L Koenig; Annika Idahl; Franco Berrino; Paolo Toniolo; Göran Hallmans; Asta Försti; Paola Muti; Per Lenner; Roy E Shore; Anne Zeleniuch-Jacquotte Journal: Cancer Epidemiol Date: 2012-05-25 Impact factor: 2.984
Authors: Tess Clendenen; Anne Zeleniuch-Jacquotte; Isaac Wirgin; Karen L Koenig; Yelena Afanasyeva; Eva Lundin; Alan A Arslan; Tomas Axelsson; Asta Försti; Göran Hallmans; Kari Hemminki; Per Lenner; Nirmal Roy; Roy E Shore; Yu Chen Journal: PLoS One Date: 2013-07-23 Impact factor: 3.240